Announcements
- NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
- NANOBIOTIX annonce une présentation de nouvelles données et du programme d’immunothérapie de Phase 1 lors de la réunion annuelle 2024 de l’American Society for Clinical Oncology (ASCO) suivi d’une conférence téléphonique et webcast
- NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
- NANOBIOTIX participera à la conférence Jefferies Global Healthcare
- NANOBIOTIX fait le point sur ses résultats financiers et opérationnels du premier trimestre 2024
- NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
- Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
- Nanobiotix annonce des avancees de la collaboration globale de developpement autour de NBTXR3 refletant son pipeline robuste et son approche de croissance sur le long terme
- Voting Rights and Shares Capital of the Company
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
More ▼
Key statistics
On Friday, Nanobiotix SA (5NRA:DEU) closed at 6.30, 63.21% above the 52 week low of 3.86 set on May 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.20 |
---|---|
High | 6.35 |
Low | 6.20 |
Bid | 6.35 |
Offer | 6.70 |
Previous close | 6.30 |
Average volume | 0.00 |
---|---|
Shares outstanding | 47.13m |
Free float | 40.40m |
P/E (TTM) | -- |
Market cap | 331.35m USD |
EPS (TTM) | -1.19 USD |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼